Drug Regulator to Monitor Side Effects (India)
This article was originally published in PharmAsia News
Executive Summary
The Central Drugs Standard Control Organisation (CDSCO), the Indian drug regulator, is planning a major overhaul in the country's drug adverse reaction monitoring system. A team of approximately 100 clinical pharmacologists across the country will be appointed to collect adverse drug reaction reports and patient complaints from hospitals, clinics, and practicing clinicians. The drug review system typically works through collecting adverse reaction reports and analyzing them in the context of safety, efficacy, and dosage compliance. It is now being proposed as a regular procedure to keep a close watch on all approved drugs in the post-marketing phase. "Though US FDA frequently publishes drug reviews and follow-up actions (recalls or restricted-use notifications) on its website, such moves are still unheard of in India," says C.J. Shishoo, trustee, Consumer Education and Research Centre, a consumer action group. According to Dr Shishoo, at least half a dozen drugs with questionable safety profiles are still being marketed in India as there were no adverse reports available with the regulator. According to a senior official from the CDSCO, "currently our mechanism is grossly inadequate to tackle the issues related to pharmacovigilance as there are no public interaction systems wherein the doctors or patients can (share) their experiences with drugs that they use (with) the regulator directly. Since the department is also facing severe people crunch, it is not able to dedicate special cells or people with the task of collecting patient responses." (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.